GRAd-COV2

{{short description|Vaccine candidate against COVID-19}}

{{Use dmy dates|date=April 2021}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image =

| alt =

| caption =

| target = SARS-CoV-2

| vaccine_type = viral

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Intramuscular

| CAS_number = 2543636-44-6

| CAS_number_Ref = {{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms =

}}

{{COVID-19 pandemic sidebar}}

GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases.{{cite journal |title=GRAd-COV2 Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04528641 |website=ClinicalTrials.gov |publisher=United States National Library of Medicine |id=NCT04528641 |date=7 January 2021}}{{cite news |url=https://finance.yahoo.com/news/reithera-announces-grad-cov2-covid-080000811.html |title=ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years |work=ReiThera Srl |publisher=Yahoo! Finance |date=24 November 2020 |access-date=12 January 2021}} It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein. More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).{{cite journal | vauthors = Capone S, Raggioli A, Gentile M, Battella S, Lahm A, Sommella A, Contino AM, Urbanowicz RA, Scala R, Barra F, Leuzzi A, Lilli E, Miselli G, Noto A, Ferraiuolo M, Talotta F, Tsoleridis T, Castilletti C, Matusali G, Colavita F, Lapa D, Meschi S, Capobianchi M, Soriani M, Folgori A, Ball JK, Colloca S, Vitelli A | display-authors = 6 | title = Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 | journal = Molecular Therapy | date = April 2021 | volume = 29 | issue = 8 | pages = 2412–2423 | pmid = 33895322 | pmc = 8062434 | doi = 10.1016/j.ymthe.2021.04.022 }}